Welcome to our dedicated page for CIBUS SEC filings (Ticker: CBUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Cibus Inc.’s leap from lab discovery to licensed crop trait often means sifting through hundreds of pages of technical language. Annual reports detail complex gene-editing pipelines, non-GMO regulatory paths, and royalty economics—yet they rarely answer questions in plain English. If you’ve ever searched for “Cibus SEC filings explained simply,” “Cibus insider trading Form 4 transactions,” or a “Cibus annual report 10-K simplified,” you know the challenge.
Stock Titan removes that friction. Our AI-powered summaries translate each section of the Cibus annual report into concise language, linking risk factors to revenue streams. The platform delivers the latest “Cibus quarterly earnings report 10-Q filing,” complete with side-by-side R&D versus cash-burn charts, and a dedicated module for “Cibus earnings report filing analysis.” Real-time alerts capture every “Cibus Form 4 insider transactions real-time,” so you can monitor Cibus executive stock transactions Form 4 before markets open. Need context on regulatory milestones? We tag each “Cibus 8-K material events explained” entry with potential impacts on trait licensing revenue.
Investors use these tools to answer practical questions:
- How do Rapid Trait Development System costs trend quarter over quarter?
- Which officers exercised options ahead of a new canola trait announcement?
- What bonuses are disclosed in the Cibus proxy statement executive compensation?
Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 2,540,536 shares of Cibus, Inc. Class A common stock, representing 4.99% of the class. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and pursuant to an investment management agreement exercises shared voting and dispositive power over those securities. Mr. Boyd, as managing member of Armistice Capital, is reported to share voting and dispositive power. The Master Fund disclaims direct beneficial ownership by reason of the management agreement. The filing states the holdings are owned in the ordinary course of business and not for the purpose of changing or influencing control.
Cibus, Inc. reported continued losses and liquidity pressure while narrowing its operational focus to commercialize rice herbicide-tolerance traits. The company recorded a $76.0 million net loss for the six months ended June 30, 2025, and used $25.4 million of cash in operating activities during that period. Cash and cash equivalents were $36.5 million versus current liabilities of $22.4 million, and an accumulated deficit of $803.4 million. Management expects to continue incurring losses and needs additional capital within a year; this raises substantial doubt about the companys ability to continue as a going concern. Cibus implemented cost reductions and a restructuring, targets annual net cash usage of approximately $30.0 million by 2026, and is prioritizing Rice weed-management traits that it estimates could represent >$200 million of annual accessible royalties upon full commercialization. The company recognized a $21.0 million goodwill impairment in Q1 2025 and completed equity transactions in Jan and Jun 2025 to raise net proceeds of about $46.4 million combined.
FAQ
What is the current stock price of CIBUS (CBUS)?
What is the market cap of CIBUS (CBUS)?
